Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Differentiating the HAE crowd

Four companies are vying to bring three different types of treatments to market for hereditary angioedema, and as of last month, all have now reported positive Phase III data. How the products get used is likely to depend in part on how physicians assess the relevance of their targets, as well as on the administration preferences of patients and physicians.

Pharming Group N.V., Lev Pharmaceuticals Inc. and Jerini AG have submitted regulatory filings, and Dyax Corp.'s product has completed Phase III testing.

All four products have Orphan Drug designation in the U.S. and the EU, and all could conceivably get to market with Orphan status. Even though Pharming (Euronext:PHARM, Leiden, the Netherlands) and Lev (LEVP,

Read the full 1151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers